Jefferies expects Anthem Biosciences’ revenue and Profit After Tax (PAT) to grow at a Compounded Annual Growth Rate (CAGR) of 18% and 20% respectively over financial year 2026-2029, driven by a …
Stocks To Buy: Analysts have a consensus bullish call, Jefferies sees 20% upside
view original post